{
  "id": 12938687,
  "title": "Scientists uncover two-pronged strategy to overcome glioblastoma's resistance to immunotherapy",
  "url": "https://urgent.news/2026/10/08/scientists-uncover-two-pronged-strategy-to-overcome-glioblastomas",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-08T19:40:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-scientists-uncover-pronged-strategy-glioblastoma.html"
  },
  "original_language": "en",
  "account": "A team of scientists at The Wistar Institute has developed a two-pronged approach to combat glioblastoma, the deadliest and most aggressive primary brain cancer in adults. The study, published in Neuro-Oncology, reveals that targeting hypoxia in the tumor environment, while simultaneously boosting T cells, can overcome the major obstacles glioblastoma presents to immunotherapy. Glioblastoma tumors are packed with myeloid cells that suppress the immune system by shutting down nearby T cells. Additionally, T cells that enter the tumor often become exhausted, making them less effective at killing cancer cells. By reducing hypoxia using axitinib, a drug already used in combination with immunotherapy, and boosting T cells with a 4-1BB agonist, the scientists were able to significantly increase median survival in preclinical mouse models from 17 days to 42 days, with a 40% long-term survival rate. The combination therapy also prevented re-growth of tumors following re-exposure, indicating lasting immune memory. While the study shows promise, it has not yet been tested in humans, but researchers hope to begin clinical trials in the near future.",
  "summary": "Scientists at The Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma. In a study published in Neuro-Oncology, the researchers show that reprogramming myeloid cells, a type of immune cell that glioblastoma tumors co-opt to protect themselves, while simultaneously boosting cancer-fighting T cells shrank the tumors and…",
  "key_points": [
    "Scientists at The Wistar Institute develop two-pronged strategy to combat glioblastoma.",
    "Targeting hypoxia and boosting T cells overcome immunotherapy obstacles.",
    "Combination therapy increases median survival from 17 to 42 days in mice."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}